Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aerie Pharmaceuticals
Biotech
Alcon’s $770M Aerie takeover delivers phase 3 dry eye wins
The lead candidate in the acquired pipeline met the primary phase 3 endpoint, positioning Alcon to file for FDA approval in the middle of the year.
Nick Paul Taylor
Jan 10, 2024 5:40am
Alcon swoops on Aerie, striking $770M buyout to expand pipeline
Aug 23, 2022 7:45am
Novartis loses cell, gene leader, digital exec—Chutes & Ladders
Sep 24, 2021 9:30am
Aerie CEO exits days after downplaying midphase eye disease flop
Sep 21, 2021 8:20am
Aerie fails its primary endpoint in eye disease test
Sep 16, 2021 4:42am
Aerie taps former Allergan exec as new VP—Chutes & Ladders
Feb 7, 2020 9:30am